Association of molecular marker O6Methylguanine DNA methyltransferase and concomitant chemoradiotherapy with survival in Southern Chinese glioblastoma patients

Hong Kong Medical Journal

Volumn 17, Issue 3, 2011, Pages 184-188

  Chan, Danny T M ^a   Kam, Michael K M ^b   Ma, Brigette B Y ^b   Ng, Stephanie C P ^a   Pang, Jesse C S ^b   Lau, Claire K Y ^a   Siu, Deyond Y W ^b   Ng, Benedict S L ^a   Zhu, X L ^a   Chen, George G ^a   Ng, H K ^b   Poon, W S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Adjuvant; Chemotherapy; Disease free survival; DNA methylation; Glioblastoma; O6 methylguanine DNA methyltransferase

Indexed keywords

ANTINEOPLASTIC AGENT; GENOMIC DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOLECULAR MARKER; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN METHYLATION; SURVIVAL TIME; TREATMENT DURATION;

ASIAN CONTINENTAL ANCESTRY GROUP; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GLIOBLASTOMA; HONG KONG; HOSPITALS, UNIVERSITY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 79958710949     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
2. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and beneft from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
3. Chan DT, Poon WS, Chan YL, Ng HK. Temozolomide in the treatment of recurrent malignant glioma in Chinese patients. Hong Kong Med J 2005;11:452-456.
4. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-797.
5. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-1354.
6. Dong SM, Pang JC, Poon WS, et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol 2001;60:808-816.
7. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-466.
8. 6-methylguanine-DNA methyltransferase in glioma and the survival time of patients [in Chinese]. Ai Zheng 2004;23:1052-1055.
9. Zhang JP, Shi HL, Sai K, et al. Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma- analysis of 42 cases [in Chinese]. Ai Zheng 2006;25:1533-1537.
10. Grasbon-Frodl EM, Kreth FW, Ruiter M, et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 2007;121:2458-2464.
11. Preusser M, Charles Janzer R, Felsberg J, et al. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 2008;18:520-532.